Transgene Biotek

3.32
-0.02
(-0.60%)
Market Cap
25.15 Cr
EPS
-0.09
PE Ratio
-
Dividend Yield
0.00 %
52 Week High
10.84
52 Week Low
3.32
PB Ratio
2.34
Debt to Equity
1.23
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
2,478.80
#1 20,720.72
50.13
#1 2,295.80
11.52
#1 362
19.34
43.44
1,007.20
10,337.53
72.42
568.60
20.11
120
35.77
47.60
1,564.55
8,023.19
53.44
1,216.80
4.59
129
15.38
34.43
679.65
3,601.70
42.34
581.30
8.63
70
29.25
36.44
787.90
2,544.11
34.57
636.40
25.65
57
49.23
52.38
1,616.75
1,387.61
29.87
86.70
25.47
32
58.82
37.91
242.42
771.15
#1 7.43
1,436.10
35.04
6
-1,081.25
49.93
369.90
262.59
21.80
63.00
#1 248.07
7
133.33
75.20
85.23
87.69
109.40
13.60
-8.11
-3
#1 142.86
51.49
120.15
83.73
66.60
36.90
6.34
1
0.00
43.10
Growth Rate
Revenue Growth
100.00 %
Net Income Growth
-88.33 %
Cash Flow Change
-
ROE
-88.42 %
ROCE
-90.95 %
EBITDA Margin (Avg.)
-72.68 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
0
0
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
Expenses
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
EBITDA
0
-0
2
2
-0
-0
-0
-0
-0
-0
0
-0
-0
-0
-0
0
-0
-1
-0
-0
-0
-0
-0
-0
0
0
-0
Operating Profit %
-86 %
0 %
-425 %
0 %
0 %
0 %
0 %
0 %
0 %
0 %
-13 %
-1,900 %
0 %
0 %
0 %
-56 %
-233 %
0 %
0 %
0 %
-120 %
-240 %
-200 %
-520 %
-820 %
-133 %
-113 %
Depreciation
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
1
1
1
1
0
0
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Profit Before Tax
-3
-3
-1
-1
-3
-3
-3
-3
-3
-3
-3
-3
-3
-3
-3
-3
-1
-2
-1
-2
-0
-0
-0
-0
0
-0
-0
Tax
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Net Profit
-3
-3
-1
-1
-3
-3
-3
-3
-3
-3
-3
-3
-3
-3
-3
-3
-1
-2
-1
-2
-0
-0
-0
-0
0
-0
-0
EPS in ₹
0.00
-0.35
-0.12
-0.10
-0.37
-0.36
-0.35
-0.37
-0.35
-0.35
-0.33
-0.34
-0.34
-0.34
-0.35
-0.34
-0.18
-0.23
-0.18
-0.19
-0.02
-0.02
-0.02
-0.04
0.03
-0.01
-0.01

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
344
313
198
187
177
167
157
147
142
142
Fixed Assets
163
141
61
51
41
31
21
11
6
6
Current Assets
18
4
1
1
1
1
1
1
1
1
Capital Work in Progress
0
0
2
2
2
2
2
2
2
2
Investments
0
0
0
0
0
0
0
0
0
0
Other Assets
180
172
135
134
134
134
134
134
134
134
Total Liabilities
344
313
198
187
177
167
157
147
142
142
Current Liabilities
25
11
12
14
13
14
14
9
11
11
Non Current Liabilities
127
127
128
120
120
120
121
121
121
121
Total Equity
191
174
59
52
44
33
22
17
11
11
Reserve & Surplus
116
99
-17
-23
-32
-43
-54
-58
-64
-65
Share Capital
76
76
76
76
76
76
76
76
76
76

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
0
0
0
0
0
-0
0
0
0
0
Investing Activities
-5
-7
0
3
2
0
0
-0
0
0
Operating Activities
4
7
0
-1
-2
0
0
0
0
0
Financing Activities
1
0
0
-2
0
-0
0
0
0
0

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
23.64 %
23.64 %
23.64 %
23.64 %
23.64 %
23.64 %
23.64 %
23.64 %
23.64 %
23.64 %
23.64 %
23.64 %
23.64 %
23.64 %
23.64 %
23.64 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
70.82 %
71.21 %
71.71 %
71.48 %
71.67 %
71.68 %
71.67 %
71.64 %
71.22 %
71.60 %
71.73 %
70.10 %
71.45 %
71.75 %
71.74 %
71.87 %
Others
5.54 %
5.15 %
4.65 %
4.88 %
4.70 %
4.69 %
4.70 %
4.72 %
5.14 %
4.77 %
4.63 %
6.26 %
4.92 %
4.61 %
4.62 %
4.50 %
No of Share Holders
10,337
10,769
10,793
11,130
11,317
11,331
11,303
11,432
11,371
11,342
11,360
12,220
12,426
12,766
12,963
13,307

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Closure of Trading Window1 day ago
Integrated Filing (Financial)Feb 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 12, 2025
The Board Has Considered And Approved The Unaudited Consolidated & Standalone Financial Results Of The Company For The Quarter Ended 31.12.2024 In Accordance With The Indian Accounting Standards (IND-Jan 24, 2025
Board Meeting Outcome for Outcome Of Board Meeting - Scrip Code 526139Jan 24, 2025
Statement Of Deviation & VariationJan 20, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 20, 2025
Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On Friday 24"January 2025Jan 16, 2025
Clarification On The Adjudication Order Received From The Enforcement Directorate Southern Regional Office.Jan 13, 2025
Closure of Trading WindowDec 31, 2024
Receipt Of Order From The Enforcement Directorate Southern Regional Office.Dec 31, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportDec 06, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMDec 05, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 15, 2024
Revised ResultsNov 13, 2024
Reg. 34 (1) Annual Report.Nov 12, 2024
Intimation Of Book Closure And Cut -Off Date For The 34Th Annual General Meeting Of Transgene Biotek Limited.Register Of Members And The Share Transfer Books Of The Company Will Remain Closed From Friday The 29Th November 2024 To Thursday The 05Th December, 2024 (Both Days Inclusive) For The Purpose Of 34Th Annual General Meeting Which Is Scheduled To Be Held On Thursday The 05Th December 2024 At IST Through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM') At 10.00 A.M. (IST).Nov 12, 2024
Outcome Of Board Meeting.This Has Reference To Our Letter Dated 03Rd November 2024.At The Meeting Of The Board Of Directors Of The Company Held On Tuesday 12Th November 2024, The Following Decisions Were Taken:1. Un- Audited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30.09.2024. (Attached).2.Limited Review Report (Standalone And Consolidated) For The Quarter And Half Year Ended 30.09.2024. (Attached).Nov 12, 2024
Board Meeting Outcome for Outcome Of Board Meeting.Nov 12, 2024
Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On Tuesday, 12Th November, 2024 At 11:00 AmNov 04, 2024
Receipt Of Legal Notice From BIRACOct 23, 2024
32(1), (3) - Statement Of Deviation & VariationOct 18, 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AOct 12, 2024
Intimation Of Non-Applicability Of Regulation 32(1) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ended On 30Th September 2024Oct 12, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 12, 2024
Compliance CertificateOct 12, 2024
Closure of Trading WindowSep 30, 2024
Extension Of Time For Holding Annual General Meeting Of The Company For The Financial Year Ended On March 31, 2024.This Is To Inform You That Registrar Of Companies, Hyderabad, Telangana, Vide Its Approval Letter Dated August 26, 2024, Has Accorded Its Approval To The Company Under Section 96 Of The Companies Act, 2013 Allowing The Company To Conduct Its Annual General Meeting For The Financial Year Ended On March 31, 2024 On Or Before December 31, 2024 I.E An Extension Of Three (3) Months To Hold The Annual General Meeting.Aug 27, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2024
1) The Board Considered And Approved The Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2024.2) The Board Considered And Approved The Limited Review Report (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2024.Aug 10, 2024
Board Meeting Outcome for Outcome Of The Board Meeting.Aug 10, 2024
Compliance-57 (5) : intimation after the end of quarterJul 21, 2024
Intimation Of Non-Applicability Of Regulation 32(1) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ended On 30Th June 2024.Jul 21, 2024
Board Meeting Intimation for This Is To Inform You That A Meeting Of Board Of Directors Will Be Held On Saturday 10Th August 2024.Jul 19, 2024
Board Meeting Intimation for This Is To Inform You That A Meeting Of Board Of Directors Will Be Held On Saturday 10Th August 2024.Jul 19, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jul 09, 2024
Board Meeting Outcome for Revised OutcomeJun 28, 2024
Closure of Trading WindowJun 28, 2024
This Is In Response To Your Email With Reference To The Above Subject On Price Movement Of Our Scrip - TRABI - 526139Jun 14, 2024
Clarification sought from Transgene Biotek LtdJun 13, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 31, 2024
Intimation On The Mistyped Date Of SAT HearingMay 31, 2024
Outcome Of Board Meeting And Submission Of Audited Financial Results For The Financial Year Ended March 31, 2024May 30, 2024
Board Meeting Outcome for Outcome Of Board Meeting And Submission Of Audited FinancialResults For The Financial Year Ended March 31, 2024May 30, 2024
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2024
Board Meeting Intimation for Intimation Of The Board Meeting Of The Company.This Is To Inform You That A Meeting Of Board Of Directors Of The Company Will Be Held On Thursday 30Th May 2024.May 12, 2024
COMPLIANCE CERTIFICATE AS PER CLAUSE 40(9) OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE YEAR ENDED 31St MARCH 2024.Apr 25, 2024
Statement Of Deviation & VariationApr 23, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Apr 23, 2024
Compliance Certificate Reg 7(3)Apr 23, 2024

Technical Indicators

RSI(14)
Neutral
28.36
ATR(14)
Less Volatile
0.31
STOCH(9,6)
Oversold
16.89
STOCH RSI(14)
Oversold
10.69
MACD(12,26)
Bearish
-0.02
ADX(14)
Strong Trend
27.23
UO(9)
Bearish
35.64
ROC(12)
Downtrend And Accelerating
-14.10
WillR(14)
Oversold
-95.89